PharmaEssentia (6446) Stock Overview
A biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6446 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
PharmaEssentia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$810.00 |
| 52 Week High | NT$859.00 |
| 52 Week Low | NT$428.03 |
| Beta | 0.43 |
| 1 Month Change | 25.19% |
| 3 Month Change | n/a |
| 1 Year Change | 79.42% |
| 3 Year Change | 166.34% |
| 5 Year Change | 911.12% |
| Change since IPO | 328.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6446 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -1.9% | 0.2% | -1.2% |
| 1Y | 79.4% | 28.7% | 90.3% |
Return vs Industry: 6446 exceeded the TW Biotechs industry which returned 28.7% over the past year.
Return vs Market: 6446 underperformed the TW Market which returned 90.3% over the past year.
Price Volatility
| 6446 volatility | |
|---|---|
| 6446 Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in TW Market | 12.3% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 6446 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6446's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Ko-Chung Lin | www.pharmaessentia.com |
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology.
PharmaEssentia Corporation Fundamentals Summary
| 6446 fundamental statistics | |
|---|---|
| Market cap | NT$301.02b |
| Earnings (TTM) | NT$5.93b |
| Revenue (TTM) | NT$17.50b |
Is 6446 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6446 income statement (TTM) | |
|---|---|
| Revenue | NT$17.50b |
| Cost of Revenue | NT$1.94b |
| Gross Profit | NT$15.56b |
| Other Expenses | NT$9.62b |
| Earnings | NT$5.93b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.96 |
| Gross Margin | 88.90% |
| Net Profit Margin | 33.89% |
| Debt/Equity Ratio | 0.1% |
How did 6446 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 23:06 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaEssentia Corporation is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Wangbin Zhou | Citigroup Inc |
| Hsuan Chen | KGI Securities Co. Ltd. |